BRISTOL-MYERS SQUIBB CO (1BMY.MI) Stock Overview
Europe - BIT:1BMY - US1101221083 - Common Stock
1BMY.MI Key Statistics, Chart & Performance
The current stock price of 1BMY.MI is 38.4 EUR. In the past month the price decreased by -20.58%.
1BMY.MI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY.DE | ELI LILLY & CO | 50.76 | 666.31B | ||
| 1LLY.MI | ELI LILLY & CO | 50.84 | 667.44B | ||
| ZEG.DE | ASTRAZENECA PLC | 18.95 | 446.01B | ||
| 1JNJ.MI | JOHNSON & JOHNSON | 18.33 | 393.86B | ||
| JNJ.DE | JOHNSON & JOHNSON | 18.02 | 387.19B | ||
| RHO.DE | ROCHE HOLDING AG-BR | 14.16 | 243.26B | ||
| 1ROG.MI | ROCHE HOLDING AG-GENUSSCHEIN | 13.94 | 239.54B | ||
| NOT.DE | NOVARTIS AG-REG | 14.84 | 215.73B | ||
| SNW.DE | SANOFI | 14.36 | 215.27B | ||
| 1SAN.MI | SANOFI | 14.36 | 215.27B | ||
| 1NOVN.MI | NOVARTIS AG-REG | 14.78 | 214.88B | ||
| SAN.PA | SANOFI | 14.19 | 212.63B |
Related stock screener links
About 1BMY.MI
Company Profile
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 34,100 full-time employees. The company is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
Company Info
BRISTOL-MYERS SQUIBB CO
Route 206 And Province Line Road
Princeton NEW JERSEY US
Employees: 34100
Phone: 16092524621
BRISTOL-MYERS SQUIBB CO / 1BMY.MI FAQ
Can you describe the business of BRISTOL-MYERS SQUIBB CO?
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 34,100 full-time employees. The company is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
What is the stock price of BRISTOL-MYERS SQUIBB CO today?
The current stock price of 1BMY.MI is 38.4 EUR. The price decreased by -3.18% in the last trading session.
What is the dividend status of BRISTOL-MYERS SQUIBB CO?
BRISTOL-MYERS SQUIBB CO (1BMY.MI) has a dividend yield of 5.72%. The yearly dividend amount is currently 2.07.
What is the ChartMill technical and fundamental rating of 1BMY stock?
1BMY.MI has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
How is the market expecting 1BMY stock to perform?
33 analysts have analysed 1BMY.MI and the average price target is 44.38 EUR. This implies a price increase of 15.57% is expected in the next year compared to the current price of 38.4.
What is the Price/Earnings (PE) ratio of BRISTOL-MYERS SQUIBB CO (1BMY.MI)?
The PE ratio for BRISTOL-MYERS SQUIBB CO (1BMY.MI) is 6.67. This is based on the reported non-GAAP earnings per share of 5.76 and the current share price of 38.4 EUR.
1BMY.MI Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to 1BMY.MI.
1BMY.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to 1BMY.MI. 1BMY.MI has an average financial health and profitability rating.
1BMY.MI Financial Highlights
Over the last trailing twelve months 1BMY.MI reported a non-GAAP Earnings per Share(EPS) of 5.76. The EPS increased by 391.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 10.58% | ||
| ROA | 5.33% | ||
| ROE | 28.96% | ||
| Debt/Equity | 2.56 |
1BMY.MI Forecast & Estimates
33 analysts have analysed 1BMY.MI and the average price target is 44.38 EUR. This implies a price increase of 15.57% is expected in the next year compared to the current price of 38.4.
For the next year, analysts expect an EPS growth of 477.64% and a revenue growth -1.12% for 1BMY.MI